TY  - JOUR
AU  - Merz, Maximilian
AU  - Jauch, Anna
AU  - Hielscher, Thomas
AU  - Bochtler, Tilmann
AU  - Schönland, Stefan Olaf
AU  - Seckinger, Anja
AU  - Hose, Dirk
AU  - Bertsch, Uta
AU  - Neben, Kai
AU  - Raab, Marc Steffen
AU  - Hillengass, Jens
AU  - Salwender, Hans
AU  - Blau, Igor Wolfgang
AU  - Lindemann, Hans-Walter
AU  - Schmidt-Wolf, Ingo G H
AU  - Scheid, Christof
AU  - Haenel, Mathias
AU  - Weisel, Katja C
AU  - Goldschmidt, Hartmut
TI  - Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
JO  - Blood advances
VL  - 2
IS  - 1
SN  - 2473-9537
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2018-01908
SP  - 1 - 9
PY  - 2018
AB  - We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30
LB  - PUB:(DE-HGF)16
C6  - pmid:29344579
C2  - pmc:PMC5761630
DO  - DOI:10.1182/bloodadvances.2017013334
UR  - https://inrepo02.dkfz.de/record/141402
ER  -